GlobeNewsWire
02 Nov 2025, 22:12 UTC · 45w ago
Verdict
Headline takes no side. We score ALVO −0.80 — strongly bearish.
−0.80strongly bearish
More negative than 88% of ticker scores this week
Which stocks this story touches
More negative than 88% of ticker scores this week
The company received an FDA complete response letter for its biosimilar candidate and lowered its 2025 revenue and EBITDA guidance.
Near neutral — 90% of ticker scores this week are stronger
Mentioned only as a strategic commercial partner with no specific impact from this news.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
Near neutral — 90% of ticker scores this week are stronger
Mentioned only as a strategic commercial partner with no specific impact from this news.
Near neutral — 90% of ticker scores this week are stronger
Mentioned only as a strategic commercial partner with no specific impact from this news.
More positive than 57% of relationship scores this week
[mutual] Alvotech has a strategic commercial partnership with Teva Pharmaceuticals.
More positive than 57% of relationship scores this week
[mutual] Alvotech has a strategic commercial partnership with Cipla.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
24/7 Wall Street
21m ago
−30.5%
Price agrees with the score
$5.32 vs $7.65 close before publication (Oct 31) · not market-adjusted
ALVO chart →
